Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**Retinal ganglion cells (RGCs)** are a type of neuron located in the ganglion cell layer of the retina and are the final output neurons connecting the retina to the brain[1][3][5][7]. Each RGC receives synaptic input from bipolar and amacrine cells that have integrated signals from photoreceptors (rods and cones)[1][3][7]. RGCs generate action potentials and transmit visual information via the optic nerve to multiple visual centers in the brain, including the lateral geniculate nucleus and the superior colliculus[1][3]. They are highly diverse, with at least 20–40 subtypes in mammals, differing in morphology, physiology, gene expression, and functional specialization for aspects such as color, motion, and contrast[3][5][6]. Subtypes include midget, parasol, and bistratified cells, as well as intrinsically photosensitive RGCs (ipRGCs), which express melanopsin and directly sense light for non-image-forming functions[3][4][5]. RGC loss is the key pathological event in glaucoma and other optic neuropathies[3][5]. While RGCs are critical in disease biology and may represent a therapeutic target cell population, they are not themselves a canonical pharmacological target such as a receptor, ion channel, or enzyme. **Note:** - There is something intrinsically incorrect about listing "Retinal ganglion cell" as a therapeutic target in the conventional molecular or drug discovery sense, as it is a heterogeneous cell population—not a single molecule, receptor, channel, or enzyme. - Therapeutic interventions may aim to protect, replace, or stimulate these cells, but drugs do not act *on* "retinal ganglion cell" as a target in the classical sense. Instead, treatments may modulate pathways within or protective factors for these neurons[3][5]. - Whenever possible, drug targeting should be specified at the molecular/protein/receptor level within RGCs (e.g., melanopsin/OPN4, neurotrophic receptor, etc.). References: See entries [1], [3], [5], [7] for the most comprehensive overview.
Not applicable for drugs (see above)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Retinal ganglion cell (RGC).